White Paper — Sponsored Content

Review of mRNA Vaccines & Therapeutics Manufacturing Challenges – Part 1 - Plasmid DNA Manufacturing

Review of mRNA Vaccines & Therapeutics Manufacturing Challenges – Part 1 - Plasmid DNA Manufacturing

Although messenger RNA (mRNA) based therapeutics have been explored for over two decades, none have reached commercialization until the first SARS-CoV-2 mRNA vaccines were developed and launched in less than 12 months by BioNtech / Pfizer and Moderna. This acceleration is due to technological advancements in RNA biology, chemistry, stability, and improved delivery system. Going forward, mRNA technology will not only help the development of other vaccines for infectious diseases, but also address non-viral gene and cell therapy applications for diseases with unmet needs.

Download White Paper

To download this white paper, complete the form below. Once submitted, you will receive a link via the email you provided to download the white paper.

Company Type

By completing this form, you consent to have your information provided to the third-party sponsor of this content and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you . ISPE will store your information in a secure environment and may use your information to provide information about relevant products, services, and other opportunities which may be of interest to you. You may unsubscribe from these ISPE communications at any time. For more information or to unsubscribe, review our Privacy Policy or contact us at ask@ispe.org.